Clinical trial
Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus…
NCT00004999 · Agouron Pharmaceuticals, Industry · Suspended
Key facts
| NCT number | NCT00004999 |
|---|---|
| Title | Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study of AG1549 in Combination With Viracept (Nelfinavir Mesylate) and Combivir (Zidovudine + Lamivudine) in Treatment-Naive HIV-Infected Patients |
| Lead sponsor | Agouron Pharmaceuticals, Industry |
| Status | Suspended |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate |
| Enrollment | 350 |
| Start date | Aug 1, 1999 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, Dominican Republic, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: